International Finance Corporation, a member of the World Bank Group, on Thursday said it was providing a loan of up to $30 million (around Rs 220 crore) to pharma company Biological E.

The loan will support the pharmaceutical firm’s expansion of low-priced, generic vaccines for routine immunisation of children and to boost capacity for manufacturing any future Covid-19 vaccine, it added.

An investment in one of India’s top vaccine manufacturers will expand access to low-cost vaccines for children in developing countries and help increase the production of a Covid-19 vaccine when developed, a key step in saving lives and restarting economies, IFC said in a statement.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

By wayne